publication date: Mar. 31, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us
and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.
It’s fair to say that eight years ago, when the Obama administration infused the economy with $800 billion in stimulus funding, policymakers likely did not expect the health information technology industry to evolve into fiefdoms guarded by legions of lawyers and walls of proprietary code.
The FDA Oncologic Drugs Advisory Committee March 29 unanimously recommended approval of a lymphoma treatment, to be administered via subcutaneous injection.
- Carlo Croce to receive 2017 AACR Margaret Foti Award for leadership, achievements in research
- Roger Lo to receive AACR-Waun Ki Hong award for outstanding achievement in cancer research
- Bezos family donates $35M to Fred Hutchinson
- Cancer death rates continue to decrease
- NCCN publishes Radiation Therapy Compendium
- NCCN Foundation awards grants to four young investigators
- Friends launches ProgressForPatients.org
- Health coalition forms National Lung Cancer Roundtable
- Columbia, New York-Presbyterian, FNIH enter research collaboration
- The Mikey Czech Foundation Contributes $1 Million To DIPG Research at Dana-Farber
- Jeffrey Ravetch gets Ross Prize in Molecular Medicine
- Alan Bernstein awarded Friesen prize
- FDA approves AstraZeneca’s Tagrisso for EGFR mutation-positive NSCLC
- FDA approves niraparib for epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Gamida Cell receives EMA orphan drug designation for NiCord
- Cota, Novartis form collaboration to advance real-world evidence in breast cancer therapies
- Novartis CAR-T cell therapy for pediatric r/r B-cell ALL gets FDA Priority Review
- BMS, Foundation Medicine form collaboration to identify predictive biomarkers across tumor types, immunotherapy agents
- AbbVie, M2Gen announce collaboration for the ORIEN Avatar Research Program